The prognostic value of circulating tumor cells in patients with melanoma

A systematic review and meta-analysis

Simone Mocellin, Dave Hoon, Alessandro Ambrosi, Donato Nitti, Carlo Riccardo Rossi

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

Background: The detection of circulating tumor cells (CTC) in patients with melanoma represents an appealing prognostic tool, but no consensus exists on this topic. We aimed to comprehensively and quantitatively summarize the evidence for the use of CTC to predict patients' clinical outcome. Methods: Fifty-three studies enrolling 5,433 patients were reviewed. Correlation of CTC status with tumor-node-metastasis disease stage and patients' overall (OS) and progression-free (PFS) survival was assessed by means of association statistics and meta-analysis, respectively. Results: CTC status correlated with both tumor-node-metastasis stage (stage I, 32%; stage II, 41.7%; stage III, 41.1%; stage IV, 47.4%; Ptrend <0.0001) and survival (OS: hazard ratio, 2.42; 95% confidence interval, 1.7-3.45, P <0.0001; PFS: hazard ratio, 2.45; 95% confidence interval, 1.78-3.38; P <0.0001). However, statistical heterogeneity was significant for both OS and PFS, likely underscoring the wide variability in study design. Furthermore, CTC positivity rates in early stages were higher and in the metastatic setting were lower than expected, which indicates an unsatisfactory accuracy of currently available CTC detection assays. Conclusions: Our findings suggest that CTC might have a clinically valuable prognostic power in patients with melanoma. However, the heterogeneity of the studies thus far published warrants caution not to overestimate the favorable results of pooled data.

Original languageEnglish
Pages (from-to)4605-4613
Number of pages9
JournalClinical Cancer Research
Volume12
Issue number15
DOIs
Publication statusPublished - Aug 1 2006

Fingerprint

Circulating Neoplastic Cells
Meta-Analysis
Melanoma
Confidence Intervals
Neoplasm Metastasis
Disease-Free Survival
Neoplasms
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The prognostic value of circulating tumor cells in patients with melanoma : A systematic review and meta-analysis. / Mocellin, Simone; Hoon, Dave; Ambrosi, Alessandro; Nitti, Donato; Rossi, Carlo Riccardo.

In: Clinical Cancer Research, Vol. 12, No. 15, 01.08.2006, p. 4605-4613.

Research output: Contribution to journalArticle

Mocellin, Simone ; Hoon, Dave ; Ambrosi, Alessandro ; Nitti, Donato ; Rossi, Carlo Riccardo. / The prognostic value of circulating tumor cells in patients with melanoma : A systematic review and meta-analysis. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 15. pp. 4605-4613.
@article{cf602c0778ef41bf852db66a16dc224f,
title = "The prognostic value of circulating tumor cells in patients with melanoma: A systematic review and meta-analysis",
abstract = "Background: The detection of circulating tumor cells (CTC) in patients with melanoma represents an appealing prognostic tool, but no consensus exists on this topic. We aimed to comprehensively and quantitatively summarize the evidence for the use of CTC to predict patients' clinical outcome. Methods: Fifty-three studies enrolling 5,433 patients were reviewed. Correlation of CTC status with tumor-node-metastasis disease stage and patients' overall (OS) and progression-free (PFS) survival was assessed by means of association statistics and meta-analysis, respectively. Results: CTC status correlated with both tumor-node-metastasis stage (stage I, 32{\%}; stage II, 41.7{\%}; stage III, 41.1{\%}; stage IV, 47.4{\%}; Ptrend <0.0001) and survival (OS: hazard ratio, 2.42; 95{\%} confidence interval, 1.7-3.45, P <0.0001; PFS: hazard ratio, 2.45; 95{\%} confidence interval, 1.78-3.38; P <0.0001). However, statistical heterogeneity was significant for both OS and PFS, likely underscoring the wide variability in study design. Furthermore, CTC positivity rates in early stages were higher and in the metastatic setting were lower than expected, which indicates an unsatisfactory accuracy of currently available CTC detection assays. Conclusions: Our findings suggest that CTC might have a clinically valuable prognostic power in patients with melanoma. However, the heterogeneity of the studies thus far published warrants caution not to overestimate the favorable results of pooled data.",
author = "Simone Mocellin and Dave Hoon and Alessandro Ambrosi and Donato Nitti and Rossi, {Carlo Riccardo}",
year = "2006",
month = "8",
day = "1",
doi = "10.1158/1078-0432.CCR-06-0823",
language = "English",
volume = "12",
pages = "4605--4613",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - The prognostic value of circulating tumor cells in patients with melanoma

T2 - A systematic review and meta-analysis

AU - Mocellin, Simone

AU - Hoon, Dave

AU - Ambrosi, Alessandro

AU - Nitti, Donato

AU - Rossi, Carlo Riccardo

PY - 2006/8/1

Y1 - 2006/8/1

N2 - Background: The detection of circulating tumor cells (CTC) in patients with melanoma represents an appealing prognostic tool, but no consensus exists on this topic. We aimed to comprehensively and quantitatively summarize the evidence for the use of CTC to predict patients' clinical outcome. Methods: Fifty-three studies enrolling 5,433 patients were reviewed. Correlation of CTC status with tumor-node-metastasis disease stage and patients' overall (OS) and progression-free (PFS) survival was assessed by means of association statistics and meta-analysis, respectively. Results: CTC status correlated with both tumor-node-metastasis stage (stage I, 32%; stage II, 41.7%; stage III, 41.1%; stage IV, 47.4%; Ptrend <0.0001) and survival (OS: hazard ratio, 2.42; 95% confidence interval, 1.7-3.45, P <0.0001; PFS: hazard ratio, 2.45; 95% confidence interval, 1.78-3.38; P <0.0001). However, statistical heterogeneity was significant for both OS and PFS, likely underscoring the wide variability in study design. Furthermore, CTC positivity rates in early stages were higher and in the metastatic setting were lower than expected, which indicates an unsatisfactory accuracy of currently available CTC detection assays. Conclusions: Our findings suggest that CTC might have a clinically valuable prognostic power in patients with melanoma. However, the heterogeneity of the studies thus far published warrants caution not to overestimate the favorable results of pooled data.

AB - Background: The detection of circulating tumor cells (CTC) in patients with melanoma represents an appealing prognostic tool, but no consensus exists on this topic. We aimed to comprehensively and quantitatively summarize the evidence for the use of CTC to predict patients' clinical outcome. Methods: Fifty-three studies enrolling 5,433 patients were reviewed. Correlation of CTC status with tumor-node-metastasis disease stage and patients' overall (OS) and progression-free (PFS) survival was assessed by means of association statistics and meta-analysis, respectively. Results: CTC status correlated with both tumor-node-metastasis stage (stage I, 32%; stage II, 41.7%; stage III, 41.1%; stage IV, 47.4%; Ptrend <0.0001) and survival (OS: hazard ratio, 2.42; 95% confidence interval, 1.7-3.45, P <0.0001; PFS: hazard ratio, 2.45; 95% confidence interval, 1.78-3.38; P <0.0001). However, statistical heterogeneity was significant for both OS and PFS, likely underscoring the wide variability in study design. Furthermore, CTC positivity rates in early stages were higher and in the metastatic setting were lower than expected, which indicates an unsatisfactory accuracy of currently available CTC detection assays. Conclusions: Our findings suggest that CTC might have a clinically valuable prognostic power in patients with melanoma. However, the heterogeneity of the studies thus far published warrants caution not to overestimate the favorable results of pooled data.

UR - http://www.scopus.com/inward/record.url?scp=33748068119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748068119&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-06-0823

DO - 10.1158/1078-0432.CCR-06-0823

M3 - Article

VL - 12

SP - 4605

EP - 4613

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 15

ER -